

Clinical Significance and Treatment of Dysrhythmias

Assessing the Patient

- O Questions to ask:
 - Ols the patient symptomatic?
 - O Does the patient need immediate treatment?
 - O How aggressive does the treatment need to be?
 - O Should pharmacologic or electrical treatment be used?



Stable vs. Unstable

- O Treatment for unstable patients:
 - O Electrical therapy
 - O Transcutaneous pacing
 - **O Cardioversion**
 - O Defibrillation



- O Treatment for stable patients:
 - O Pharmacologic agents

Stable vs. Unstable

- O Signs and symptoms of instability:
 - O Decreased cardiac output
 - O Chest pain
 - O Shortness of breath
 - **O** Hypotension
 - **OCHF**
 - O Pulmonary edema



Treating the Patient

O Must decide what modality to use



Electrical Therapy

- O Cardioversion and defibrillation
 - O Fundamental goal
 - O Primary differences
 - ODefibrillation is unsynchronized
 - O Reserved for life-threatening conditions
 - OCardioversion is synchronized
 - OUsed when there is underlying organized rhythm

Electrical Therapy

- O Sedation
 - O Cardioversion is painful and vascular access is required
 - OUsually requires higher doses than transcutaneous pacing
- O Transcutaneous pacing
 - O Usually effective for all symptomatic bradycardias
 - O Contraindication
 - O May also be used for Torsades de Pointes

- O Atropine Sulfate
 - O Is a parasympatholytic
 - O Increases HR and conduction velocity
 - O Should never be administered slowly
 - O Usually effective for:
 - OSinus bradycardia
 - OSinus arrest / Sinus exit block
 - OSecond degree AV block, type I
 - Olf the QRS is narrow, second degree 2:1 and advanced AV block and third degree AV block

- O Atropine Sulfate
 - O Ineffective for:
 - OSecond degree, type II AV block
 - OIf wide QRS, second degree 2:1 and advanced AV block and third degree AV block
 - OTreatment of bradycardia in heart transplant patients
 - O Use with caution in acute MI patients

- O Vasopressors
 - O Definition
 - O Increases CO by increasing HR and strength of cardiac contraction
 - O Types:
 - **OEpinephrine**
 - **OVasopressin**
 - **O**Dopamine
 - ONorepinephrine
 - **ODobutamine**
 - Olsoproterenol

- O Epinephrine
 - **O** Considerations
 - O Stimulates heart muscle directly
 - O May result in too fast a HR
 - O Can cause irritability
 - O Can cause PVCs, V Tach, or V Fib to occur
 - O Should be administered via a diluted infusion

- O Vasopressin
 - O Nonadrenergic peripheral vasoconstrictor
 - O Equivalent to epinephrine in certain conditions
- O Dopamine
 - O Naturally occurring precursor of norepinephrine in body
 - O Considered for treatment of symptomatic bradycardias
 - O Must use caution when administering

- O Norepinephrine
 - O Naturally occurring potent vasoconstrictor and inotropic agent
 - O May be effective for patients with severe hypotension
 - O Contraindicated in hypovolemic patients
 - O May increase myocardial O2 requirements
- O Dobutamine
 - O Useful for treatment of severe systolic heart failure and reducing pulmonary edema

- **O Antidysrhythmics**
 - O Types:
 - **OAdenosine**
 - **OAmiodarone**
 - **OLidocaine**
 - **OProcainamide**
 - **OMagnesium**
 - **OI butilide**

- O Adenosine
 - O Briefly depresses AV node and sinus node activity
 - O Indicated for:
 - **OSVT**
 - O Contraindications:
 - **OAtrial flutter**
 - **OA Fib**
 - OAtrial or ventricular tachycardias

- O Amiodarone
 - O Affects sodium, potassium, and calcium channels
 - O Indicated in:
 - **OTachycardias**
 - **OCardiac Arrest**
 - O Adverse effects:
 - **OHypotension**
 - **OBradycardia**

- O Lidocaine
 - O Little scientific evidence to support use
 - O Toxic reactions and side effects:
 - **OSlurred** speech
 - **OAltered consciousness**
 - **OMuscle twitching**
 - **OSeizures**
 - OBradycardia

- O Procainamide
 - O Suppresses atrial and ventricular dysrhythmias
 - O Used for V Tach, A Fib, Atrial Flutter
- O Magnesium
 - O Electrolyte
 - O Cofactor in neurochemical transmission and muscular excitability

- O Ibutilide
 - O Short-acting
 - O Prolongs action potential duration
 - O Increases refractory period of myocardium
 - O Used in:
 - OA Fib
 - **OAtrial flutter**
 - O Has minimal effects on BP and HR
 - O Relatively high incidence of ventricular dysrhythmia

- O Calcium Channel Blockers
 - O Diltiazem and Verapamil
 - **OSlow conduction**
 - Olncrease conduction time through AV node
 - OCan be used in:
 - **OSVT**
 - O Stable, narrow-complex, ectopic focus tachycardias
 - OA Fib
 - O Atrial flutter

- O Bradycardias
 - O Includes:
 - OSinus bradycardia
 - OSinus arrest/sinus exit block
 - O2nd degree AV block, Type I
 - O2nd degree 2:1 and Advanced AV block with narrow QRS
 - O3rd degree AV block with narrow QRS

- O Bradycardias
 - O Treatment:
 - **OOxygen**
 - OAtropine sulfate AND/OR trancutaneous pacing
 - ODopamine or epinephrine infusion
 - **OTransvenous pacemaker**

- O Heart blocks
 - O Includes:
 - O2nd degree type II AV block
 - O 2nd degree 2:1 and Advanced AV block with wide QRS
 - O3rd degree AV block with wide QRS
 - O Treatment:
 - OOxygen
 - **OTranscutaneous pacing**
 - ODopamine or epinephrine infusion
 - **OTransvenous pacemaker**

- O Escape rhythms
 - O Includes:
 - OJunctional escape rhythm
 - OVentricular escape rhythm
 - O Treatment:
 - **OOxygen**
 - **OTranscutaneous pacing**
 - ODopamine or epinephrine infusion

- O Sinus tachycardia and atrial tachycardia with block
 - OTreatment:
 - ONo specific treatment
 - **OTreat underlying cause**
 - ODiscontinue any responsible drugs

- O Narrow QRS tachycardia of unknown origin with pulse
 - O Treatment:
 - OOxygen
 - **OVagal maneuvers**
 - **OAdenosine**
 - ODetermine if dysrhythmia is:
 - O Paraoxysmal SVT (PSVT)
 - O Atrial tachycardia without block
 - O Junctional tachycardia
 - O Atrial flutter/fibrillation

- O Atrial tachycardia without block
 - O Treatment:
 - O Oxygen
 - O Diltiazem or beta-blocker or amiodarone
- O PSVT with narrow QRS
 - O Treatment:
 - O Oxygen
 - O Vagal maneuvers
 - O Adenosine, diltiazem, or beta-blocker
 - O Digoxin
 - O Cardioversion

- O Junctional tachycardia
 - O Treatment:
 - **O**Oxygen
 - OAmiodarone or beta-blocker
- O Atrial flutter/atrial fibrillation
 - O Treatment to control HR:
 - **O**Oxygen
 - OBeta-blocker or diltiazem
 - **ODigoxin**

- O Atrial fibrillation < 48 hours
 - O Treatment to convert the rhythm:
 - O Oxygen
 - O I butilide, amiodarone, or procainamide
 - O Cardioversion
- O Atrial fibrillation > 48 hours or of unknown duration
 - O Treatment to convert the rhythm:
 - O Oxygen
 - O Delay cardioversion until patient is anticoagulated and atrial thrombi excluded
 - O Cardioversion and amiodarone if patient unstable

- Wide QRS Tachycardia of unknown origin with pulse
 - O Treatment to convert rhythm:
 - O Oxygen
 - O Cardioversion
 - O Adenosine or amiodarone
- O Monomorphic V tach with pulse
 - O Treatment to convert rhythm:
 - O Oxygen
 - O Cardioversion
 - O Amiodarone, lidocaine, or procainamide

- O Polymorphic V tach with pulse and normal baseline QT interval
 - O Treatment to convert rhythm:
 - OOxygen
 - OCorrect any electrolyte imbalance
 - **OCardioversion**
 - OBeta-blocker
 - OAmiodarone, lidocaine, or procainamide

- O Polymorphic V tach with pulse and prolonged baseline QT interval torsades de pointes with pulse
 - O Treatment to convert rhythm:
 - O Oxygen
 - O Correct any electrolyte imbalance
 - O Magnesium sulfate
 - O Transcutaneous overdrive pacing and betablocker
 - O Defibrillation
 - O Discontinue amiodarone, procainamide, betablockers, or agents prolonging QT interval

- **O PACs and PJCs**
 - O Treatment:
 - ODiscontinue stimulants and sympathomimetic drugs
 - **OWithhold digitalis**
 - ODigibind if digitalis toxicity confirmed

- **OPVCs**
 - O Treatment:
 - **OOxygen**
 - Oldentify and correct any underlying causes of PVCs
 - OConsider one of following:
 - O Beta-blocker
 - **O** Amiodarone
 - **OLidocaine**
 - O Procainamide

- O V Fib/pulseless V Tach
 - O Unmonitored/monitored cardiac arrest:
 - **OCPR**
 - **ODefibrillation**
 - OVasopressin or epinephrine
 - **OAmiodarone**
 - **OMagnesium sulfate**

- Asystole
 - O Unmonitored/monitored cardiac arrest:
 - **OCPR**
 - OVasopressin or epinephrine
- O Pulseless electrical activity
 - O Unmonitored/monitored cardiac arrest:
 - **OCPR**
 - OVasopressin or epinephrine
 - OTreat underlying cause if known

Drugs Used to Treat Dysrhythmias

Drug	Class
Adenosine (Adenocard)	Antidysrhythmic
Amiodarone (Cordarone)	Antidysrhythmic
Atropine sulfate	Anticholinergic
Beta-blockers: Atenolol (Tenormin) Esmolol HCL (Brevibloc) Metoprolol (Toprol, Lopressor)	Beta-adrenergic blocking agent
Diazepam (Valium)	Tranquilizer, amnesiac, sedative
Digoxin (Lanoxin)	Antidysrhythmic, inotropic agent, digitalis glycoside
Diltiazem (Cardizem)	Calcium channel blocker

Drugs Used to Treat Dysrhythmias

Drug	Class
Dobutamine (Dobutrex)	Adrenergic agent
Dopamine (Intropin)	Adrenergic agent
Epinephrine (Adrenalin Chloride)	Adrenergic agent
Ibutilide (Corvert)	Antidysrhythmic
Lidocaine (Xylocaine)	Antidysrhythmic
Magnesium sulfate	Electrolyte
Midazolam (Versed)	Sedative, tranquilizer, amnesiac
Morphine sulfate	Narcotic, analgesic
Nitroglycerin (Nitrostat, Nitrol, Tridil, etc.)	Antianginal agent, vasodilator

Drugs Used to Treat Dysrhythmias

Drug	Class
Norepinephrine (Levophed)	Adrenergic agent
Procainamide (Pronestyl)	Antidysrhythmic
Vasopressin	Vasoconstrictor

Reference

O Wesley, K. (2011). Huszar's Basic Dysrhythmias and Acute Coronary Syndromes: Interpretation and Management, 4th Edition. St. Louis: Elsevier.

